 BURLINGAME, Calif., Feb. 12, 2021 GLOBE NEWSWIRE -- Corvus Pharmaceuticals, Inc. NASDAQ:CRVS, a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 8,571,429 shares of its common stock at a price to the public of 3.50 per share, for gross proceeds of 30.0 million before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by Corvus. All of the shares are being offered by Corvus. In addition, Corvus has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,285,714 shares of common stock at the public offering price, less underwriting discounts and commissions. 